跳至主要内容
临床试验/NCT00373789
NCT00373789终止3 期

Refractory Urge Incontinence and Botox Injections

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)8 个研究点 分布在 1 个国家目标入组 87 人开始时间: 2006年6月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
终止
发起方
入组人数
87
试验地点
8
主要终点
Time to recurrence of detrusor overactivity incontinence symptoms

研究概览

简要总结

The purpose of this study is to see whether Botox A (injected into the bladder muscle) can improve symptoms of urge incontinence that has not improved with usual medical treatments.

详细描述

Women who suffer with urge incontinence may not get relief with usual medical treatment (such as medications or behavioral techniques). We plan to enroll women with refractory urge incontinence in centers across the US. Study participants will undergo cystoscopy (telescope look into the bladder) and injection of either Botox A or placebo. If symptoms are not adequately relieved, subjects participants will receive a second injection that is Botox A. Participants are interviewed monthly by study personnel to determine symptoms and health status.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Outcomes Assessor)

入排标准

年龄范围
21 Years 至 —(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • Adult women
  • Detrusor overactivity incontinence confirmed by urodynamic testing
  • Symptoms refractory to standard first- and second-line treatments
  • 6 or more urge incontinence episodes on 3-day bladder diary
  • Normal neurological examination

排除标准

  • Urinary retention
  • Allergy to Botox (Botulinum Toxin A)
  • Previous bladder treatment with Botox (Botulinum Toxin A) in the past year
  • Pregnancy or planning pregnancy within next year
  • Neurologic disease with impaired neurotransmission

研究组 & 干预措施

Botox A

Experimental

up to two injections of 200 Units of intra-detrusor Botulinum Toxin A , which must be separated by at least eight weeks and no more than 52 weeks

干预措施: Botulinum Toxin A, bladder detrusor muscle injection (Drug)

Placebo

Placebo Comparator

up to two injections of inactive injection (carrier saline), which must be separated by at least eight weeks and no more than 52 weeks

干预措施: Vehicle saline as placebo (Drug)

结局指标

主要结局

Time to recurrence of detrusor overactivity incontinence symptoms

时间窗: 6 months

To allow sufficient time for the onset of action of botulinum toxin A, the earliest outcome measurement was 60 days after injection. Failure was defined as a patient global impression of improvement (PGI-I) score of 4 or greater, the commencement of any new treatment at any time after the first injection or increased intensity of previously established treatment for DOI.

次要结局

  • Change in incontinence episode frequency by bladder diary(At 12 mos after first injection., but no less than 1 mo after second injection)
  • Incontinence-related and health-related quality of life(At 12 mos after first injection, but no less than 1 mo after second injection.)
  • Voiding dysfunction requiring catheterization(throughout 12-month study)

研究者

发起方
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
申办方类型
Nih

研究点 (8)

Loading locations...

相似试验

Refractory Urge Incontinence and Botox Injections | 临床试验